EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis

Anthony Vocat, Amanda Luraschi-Eggemann, Claudia Antoni, Gino Cathomen, Danuta Cichocka, Gilbert Greub iD, Olga Riabova, Vadim Makarov iD, Onya Opota, Alfonso Mendoza, Stewart T Cole iD, Alexander Sturm iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01318-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Anthony Vocat und 11 weiteren Autor:innen. Beteiligte Einrichtung: Resistell AG, Muttenz, Switzerland. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antitubercular Agents, Thiazines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel drugs and improved diagnostics for Mycobacterium tuberculosis (MTB) are urgently needed and go hand in hand. We evaluated the in vitro activity of two benzothiazinone drug candidates (MCZ, PBTZ169; BTZ043) and their main metabolites against MTB using advanced nanomotion technology. The results demonstrated significant reductions in MTB viability within 7 h, indicating the potential for rapid, precise antibiotic susceptibility testing based on a phenotypic read-out in real time. PBTZ169 and H 2 -PBTZ169 achieved 100% separation between the susceptible H37Rv and a resistant dprE1 mutant strain NTB1. These findings support nanomotion technology’s potential for faster antibiotic susceptibility testing of novel MTB drug candidates targeting the DprE1 enzyme that could reduce empirical treatment duration and antibiotic resistance selection pressure due to inaccurate treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisAntitubercular AgentsThiazinesMicrobial Sensitivity TestsBacterial ProteinsAlcohol OxidoreductasesPiperazines

Stichwörter der Autor:innen

DprE1 inhibitorsMycobacterium tuberculosisantibiotic susceptibility testmacozinonenanomotion

Substanzen

Antitubercular AgentsmacozinoneThiazinesBacterial ProteinsDprE1 protein, Mycobacterium tuberculosisAlcohol OxidoreductasesPiperazines

Autor:innen und Institutionen

  • Resistell AG, Muttenz, Switzerland.
  • Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Innovative Medicines for Tuberculosis (iM4TB), Lausanne, Switzerland.
  • Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Research Centre of Biotechnology RAS, Leninsky Prospect, Moscow, Russia.

ORCID-Profile: Gilbert Greub, Vadim Makarov, Stewart T Cole, Alexander Sturm

Zitieren

APA

Vocat, A., Luraschi-Eggemann, A., Antoni, C., Cathomen, G., Cichocka, D., Greub, G., Riabova, O., Makarov, V., Opota, O., Mendoza, A., Cole, S. T., & Sturm, A. (2025). Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01318-24

Vancouver

Vocat A, Luraschi-Eggemann A, Antoni C, Cathomen G, Cichocka D, Greub G, et al. Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01318-24

BibTeX
@article{Vocat2025,
  author = {Vocat, Anthony and Luraschi-Eggemann, Amanda and Antoni, Claudia and Cathomen, Gino and Cichocka, Danuta and Greub, Gilbert and Riabova, Olga and Makarov, Vadim and Opota, Onya and Mendoza, Alfonso and Cole, Stewart T and Sturm, Alexander},
  title = {Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01318-24}
}
Kostenlos starten →